Menu
View Cart  

Recommended Products

Visit Store
Gmp-inspection-preparation-checklist-130x160

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological-risk-eval-and-mngmnt-for-md-130x160

Biological Risk Evaluation and Management for Medical Devices

Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.

Events

View All
Jan 29

Developing Pharmaceutical Investigational Brochures & Annual Reports: Secrets to Practical Succes...

Jan 30

Regulating Software Used by Life Science Manufacturers: Is it a Medical Device or Not?

Feb 13

Building a World-Class Drug Supply Chain: Tips for Compliance and Digital Transformation

Feb 19

Medical Device Risk Management: Prepare for the Winds of Change

Mar 20

Medical Device Complaint Management: Escape the Labyrinth

Mar 26

Conducting Advanced Root Cause Analysis and CAPA Investigations

Editor's Picks

View all
Clearancestamp_orange

Gramercy’s Nitinol Staple System Cleared by FDA

The device provides an array of sterile symmetric and asymmetric, barbed and smooth staples.
Fda_logo_black_2016

Stakeholders Offer Feedback on New National Drug Code Format

Among other options, the agency proposed a new, expanded 12-digit format.

BIOMIRA REPORTS LUNG CANCER DRUG STUDY RESULTS

KEYWORDS Drug Pipeline Alert
A A

Biomira has reported results from a clinical trial of its non-small cell lung cancer drug, Stimuvax.

The final survival results from an analysis of the Phase IIb data confirmed a median survival in patients with Stage IIIB cancer of 30.6 months with Stimuvax, while patients in the same stage who were in a control test group had a median survival of 13.3 months.